Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents

被引：0
|
作者：
Finn, R. S.
Lau, A.
Kalous, O.
Conklin, D.
Dering, J.
Knights, C.
O'Shaughnessy, A.
Cranston, A.
Riches, L.
Carmichael, J.
O'Connor, M. J.
Slamon, D. J.
机构：
[1] KuDOS Pharmaceut, Cambridge, England
[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117S / 117S
页数：1
相关论文
共 50 条
  • [1] Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer
    O'Connor, M. J.
    Lau, A.
    Finn, R. S.
    Knights, C.
    O'Shaughnessy, A.
    Kalous, O.
    Conklin, D.
    Riches, L.
    Carmichael, J.
    Slamon, D. J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 175 - 176
  • [2] Pre-clinical pharmacology of the novel PARP inhibitor, AZD2281 (KU-0059436)
    Cranston, A. N.
    Moore, S.
    Beaudoin, L.
    Lau, A.
    Lewis, L.
    Copsey, L.
    O'Connor, M. J.
    Menear, K. A.
    Smith, G. C. M.
    Martin, N. M. B.
    EJC SUPPLEMENTS, 2008, 6 (12): : 154 - 154
  • [3] The PARP inhibitor AZD2281 induces autophagy and complete cell death in BRCA mutant breast cancer cell lines
    Akar, Ugur
    Barrera, Angelica Gutierrez
    Hortobagyi, Gabriel N.
    Arun, Banu
    CANCER RESEARCH, 2012, 72
  • [4] Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer
    Knights, Charlotte
    Riches, Lucy
    Lau, Alan
    Mangena, Ramu
    Avis, Tim
    Finn, Richard
    O'Shaughnessy, Aisling
    Cranston, Aaron
    Kalous, Ondrej
    Conklin, Dylan
    Carmichael, James
    Slamon, Dennis
    O'Connor, Mark
    CANCER RESEARCH, 2009, 69
  • [5] Sequence specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin.
    Hays, J. L.
    Kim, G.
    Mariani, J.
    Murphy, R. F.
    Angelos, M.
    McCollum, A.
    Lu, J.
    Widemann, B. C.
    Lee, J.
    Kohn, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer
    Liu, J.
    Fleming, G. F.
    Tolaney, S. M.
    Birrer, M. J.
    Penson, R. T.
    Berlin, S. T.
    Whalen, C.
    Tyburski, K.
    Matijevich, K.
    Kasparian, E.
    Roche, M.
    Lee, H.
    Winer, E. P.
    Ivy, S. P.
    Matulonis, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Synergistic effect of olaparib (AZD2281) with combination of cisplatin on PTEN-deficient lung cancer cell lines
    Minami, Daisuke
    Takigawa, Nagio
    Takeda, Hiromasa
    Takata, Minoru
    Ichihara, Eiki
    Hisamoto, Akiko
    Hotta, Katsyuyuki
    Tabata, Masahiro
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2012, 72
  • [8] The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
    Arun, Banu
    Akar, Ugur
    Gutierrez-Barrera, Angelica M.
    Hortobagyi, Gabriel N.
    Ozpolat, Bulent
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) : 262 - 268
  • [9] Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.
    Cotte, Alexia
    Beniey, Michele
    Haque, Takrima
    Bechir, Nelly
    Hubert, Audrey
    Diallo, Korotoum W.
    Tran-Thanh, Danh
    Hassan, Saima N.
    CANCER RESEARCH, 2021, 81 (13)
  • [10] The Poly (ADP-Ribose) Polymerase-1 Inhibitor, AZD2281, enhances radiation response of breast cancer cells by inhibiting DNA repair
    Mehta, Meghna
    Munshi, Anupama
    CANCER RESEARCH, 2012, 72
12345